SANTRAL SİNİR SİSTEMİ LENFOMA OTOLOG KÖK HÜCRE NAKLİ HAZIRLIK PROTOKOLÜ

Kaynaklar:

1-Panageas KS, Elkin EB, DeAngelis LM, Ben-Porat L, Abrey LE. Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis. Cancer 2005; 104: 2466–2472.

2-Shiels MS, Pfeiffer RM, Besson C, Clarke CA, Morton LM, Nogueira L et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol 2016; 174: 417–424.

3-Rubenstein JL, Hsi ED, Johnson JL, Jung S-H, Nakashima MO, Grant B et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 2013; 31: 3061–3068.

4-Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 2013; 31: 3971–3979.

5-Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH et al. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG Oncology RTOG 0227. J Clin Oncol 2016; 34: 1620–1625.

6-Kasenda, B., G. Ihorst, R. Schroers, et al. 2017. "High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group." Leukemia 31(12):2623-2629.

7-Illerhaus, G., B. Kasenda, G. Ihorst, et al. 2016. “High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial.” Lancet Haematol 3(8):e388-e397.

8-Illerhaus, G., R. Marks, G. Ihorst et al. 2006. "High-Dose Chemotherapy with Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy as First-Line Treatment of Primary CNS Lymphoma." J Clin Oncol 24(24) 3865-3870.